Bacterial and viral specimen collection market seen reaching $44.98 billion by 2030

The Business Research Company says the bacterial and viral specimen collection market is expanding quickly, driven by higher infectious disease testing, better sample handling and broader use of molecular diagnostics. The market is projected to rise from $23.86 billion in 2025 to $44.98 billion by 2030, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - Bacterial and viral specimen collection is central to diagnosing infectious diseases and guiding treatment. - Faster testing, stronger infection control and better transport systems are expanding demand for collection kits and related services. - The market’s growth signals more spending across labs, healthcare systems and diagnostic suppliers.

What happened: - The Business Research Company released its Bacterial and Viral Specimen Collection Global Market Report 2026. - The report estimates the market will grow from $23.86 billion in 2025 to $27.14 billion in 2026. - The report forecasts the market will reach $44.98 billion by 2030. - The forecast implies a 13.7% CAGR from 2025 to 2026 and a 13.5% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - Download a free sample of the market report - View the full market report

The details: - Bacterial and viral specimen collection includes gathering biological samples such as nasal swabs, throat swabs, body fluids and tissue biopsies. - The process uses sterile tools, accurate collection methods and proper storage or transport to preserve microorganism viability. - Historical growth has been supported by more infectious disease cases, higher diagnostic test volumes and the growth of centralized laboratory testing. - Better awareness of specimen handling and improvements in sample transport infrastructure also supported growth. - The forecast period is expected to benefit from stronger demand for rapid diagnostic testing. - Wider use of decentralized healthcare services and molecular diagnostic methods is also expected to support expansion. - The report points to increased focus on pandemic preparedness and research into emerging pathogens. - Key trends include sterile and standardized collection kits, transport media with longer stability, infection control protocols, home-based collection, point-of-care collection, and stronger sample traceability. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report set also includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, hotspot infographics, and updated graphics and tables.

Between the lines: - Rising infectious disease rates are doing more than lifting test volumes; they are pushing buyers toward more reliable collection systems that reduce contamination and sample loss. - The shift toward home-based and point-of-care collection suggests specimen collection is moving closer to patients, not just deeper into hospital labs. - A strong Asia-Pacific growth outlook points to rising diagnostic capacity and healthcare expansion outside mature Western markets. - CDC data cited in the release show tuberculosis cases in the U.S. rose from 8,320 in 2022 to 9,615 in 2023, with the incidence rate increasing from 2.5 to 2.9 per 100,000 people.

What's next: - The market is likely to keep expanding as infectious disease testing demand rises and molecular diagnostics become more common. - Product development will likely center on standardized kits, longer-lasting transport media and better traceability. - Healthcare providers and diagnostic companies may continue shifting toward decentralized and point-of-care collection models. - Follow the company on LinkedIn - See the company's LinkedIn page - See the company's Facebook page - See the company's X account